Questions Remain For Samsung Bioepis Post-Biogen
Management Changes, Strategic Focus And Structural Aspects Yet To Be Decided
In exclusive comments made to Generics Bulletin, Samsung Biologics has acknowledged that it has yet to decide on several aspects of Samsung Bioepis’ management, structure and strategic focus once Biogen completes the sale of its stake in the biosimilars joint venture to its partner.
You may also be interested in...
Samsung Biologics has reiterated the importance of biosimilars to its business in the wake of its move to buy out partner Biogen’s stake in their Samsung Bioepis biosimilars joint venture.
Looking back over the first quarter of 2022, Generics Bulletin executive editor David Wallace picks out highlights from January to March that include a number of major deals in the biosimilars sector, warnings of increasing price pressure on generics, and key strategy updates from companies across the off-patent sector.
Takeda spins out Oak Hill Bio, Lupin and Axantia will co-develop filgrastim biosimilar and Xbiome licenses skin ulcer candidate from Aurealis.